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Abstract 33 
The rehabilitation of Covid-19 patients after prolonged intensive care unit treatment is often 34 
complex and challenging. Patients may suffer a myriad of long-term multi-organ impairments 35 
affecting the respiratory, cardiac, neurological, digestive and musculoskeletal systems. Skeletal 36 
muscle dysfunction of respiratory and limb muscles, commonly referred to as intensive care 37 
unit acquired weakness, occurs in around 40% of all patients admitted to intensive care. The 38 
impact on mobility and return to activities of daily living is severe. Furthermore, many patients 39 
suffer ongoing symptoms of fatigue, weakness and shortness of breath in what is being 40 
described as “Long Covid”. Neuromuscular electrical stimulation is a technique in which small 41 
electrical impulses are applied to skeletal muscle to cause contractions when voluntary muscle 42 
contraction is difficult or impossible. Neuromuscular electrical stimulation can prevent muscle 43 
atrophy, improve muscle strength and function, maintain blood flow and reduce oedema. This 44 
review examines the evidence, current guidelines, and proposed benefits of using 45 
neuromuscular electrical stimulation with patients admitted to the intensive care unit. Practical 46 
recommendations for using electrical muscle stimulation with Covid-19 patients are provided 47 
and suggestions for further research are proposed.   48 
 49 
Keywords: critical care; rehabilitation; neuromuscular electrical stimulation; muscular 50 
atrophy; coronavirus infections; Covid-19 51 
 52 
Lay Abstract 53 
Many patients with Covid-19 who are admitted to the intensive care unit suffer ongoing 54 
symptoms of fatigue, weakness and shortness of breath. Neuromuscular electrical stimulation 55 
is a technique in which small electrical impulses are applied to skeletal muscle to cause 56 
contractions when voluntary muscle contraction is difficult or impossible. It can prevent 57 
muscle atrophy, improve muscle strength and function, maintain blood flow and reduce 58 
oedema. This review examines the evidence, current guidelines, and proposed benefits of 59 
using neuromuscular electrical stimulation with patients admitted to the intensive care unit. 60 
Practical recommendations for using electrical muscle stimulation with Covid-19 patients are 61 
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Background 67 
The COVID-19 (C-19) pandemic has seen unprecedented numbers of people being treated in 68 
Intensive Care Units (ICUs) throughout the world. Many patients have received artificial 69 
ventilation, and some have been ventilated for many weeks. Those that survive are often left 70 
with long term disabilities as a result of the effects of both the disease and of the treatments 71 
necessary to keep them alive. A myriad of multi-organ impairments is associated with C-19 72 
including respiratory, cardiac, neurological, bowel and kidney dysfunction (1). The 73 
unexpectedly large number of C-19 patients requiring a prolonged ICU stay additionally 74 
increases the risk of dysfunction of both respiratory and skeletal muscle, commonly referred to 75 
as ICU acquired weakness (ICUAW). A conspicuous feature of C-19 is the persistence of 76 
symptoms, which may appear to resolve but then recur. As a result, many survivors are left 77 
needing significant rehabilitation at a time when such services are under great stress. This has 78 
led to the blanket term “Long Covid”, which describes ongoing fatigue, weakness and delayed 79 
recovery (2).  80 
 81 
Strikingly, in the first seven months of 2020, there were more than 10,000 C-19 admissions to 82 
critical care in the United Kingdom (UK) National Health Service (NHS), which is four times 83 
greater than historic annual viral pneumonia cases (3). Our experience of C-19 in the UK is 84 
that critically unwell patients generally require a longer course of respiratory support, 85 
exacerbating other risk factors for ICUAW (Table 1) (3). At present, ICUAW is seen in around 86 
20-50% of C-19 patients admitted to the ICU (4). General deconditioning, muscle atrophy, 87 
inflammation, and functional disability often necessitates transfer from the ICU to a long-term 88 
care facility. Exacerbations of chronic comorbidities and the cycle of prolonged bed rest, 89 
ongoing inflammation and malnutrition can lead to continued functional disability, immobility 90 
and continued ventilation support. Data from the UK Intensive Care National Audit and 91 
Research Centre (ICNARC) database indicates that older age, obesity, multiple deprivation, 92 
and the requirement for assistance in the activities of daily living are predictors for severe 93 
disease requiring admission to Critical Care (3). These risk factors are associated with a 94 
reduced level of background fitness, malnutrition and neuropathy. Infection with C-19 95 
characteristically causes myalgia, lethargy and a loss of appetite likely to exacerbate this pre-96 
morbid condition. Further deconditioning may result from constrained normal daily activities. 97 
This may be due to the disease itself, causing shortness of breath on exertion or delirium (5), 98 
or may be the  result of supportive interventions and infection control measures. It is also 99 
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noteworthy that proximal myopathy is associated with the use of therapeutic dexamethasone, 100 
a drug that has been shown to reduce 28 day mortality in C-19 (6).  101 
 102 
After leaving hospital, almost 90% of survivors experience ongoing symptoms for more than 103 
two months, such as fatigue and shortness of breath, which are likely to limit rehabilitation and 104 
potentiate deconditioning (7). ICUAW is associated with worse outcomes, including a nearly 105 
two-fold increase in one-year mortality, and decreased quality of life (8, 9).  A major challenge 106 
within current practice is how to ameliorate profound physical and functional deficits in C-19 107 
survivors at a time where traditional services are stretched. Innovations that reduce the duration 108 
and improve the outcome of rehabilitation will alleviate the burden of suffering and economic 109 
damage caused by C-19.  110 
 111 
Neuromuscular electrical stimulation (NMES) is the application of small electrical impulses to 112 
nerves supplying muscles using  electrodes applied to the skin and has long been used as a 113 
treatment for muscle weakness (10). NMES can be used to induce a muscle contraction when 114 
it is difficult or impossible for the person to achieve this voluntarily thereby allowing effective 115 
exercise and the strengthening of muscles. NMES has been proposed as an intervention to 116 
address immobilisation and ICUAW in severe C-19 patients (11), however details on when and 117 
how to utilise NMES are lacking. As post-acute rehabilitation services respond to the 118 
increasing demand on services; recommendations are required to guide the delivery of 119 
rehabilitation models. This narrative review critically examines the evidence for using NMES 120 
in the ICU and offers suggestions for clinical practice among C-19 patients. This article 121 
provides practical recommendations using a continuum of care model for clinicians interested 122 
in using electrical stimulation for patients during and after prolonged ICU treatment.  123 
 124 
Methodology 125 
This narrative review was informed by the findings of a web-based literature search, completed 126 
in October 2020. The search aimed to identify studies that have investigated the role of 127 
electrical stimulation in the recovery of patients admitted to the ICU and published in the last 128 
ten years (January 2010-October 2020). A search strategy (supplementary material 1) was 129 
developed to capture randomised controlled trials or non-randomised clinical trials that have 130 
evaluated an intervention of electrical stimulation (FES or NMES) in patients admitted to the 131 
ICU. Specifically, we sought studies of adults (aged over 18 years), admitted to the ICU due to 132 
chronic illness or following non-elective surgery, who received an intervention of electrical 133 
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stimulation, either i) during their stay in the ICU, ii) during the acute recovery phase in hospital, 134 
or iii) following discharge from hospital. The databases searched included: PubMed, 135 
EMBASE, Medline, CINAHL Complete, and The Cochrane Library. Articles were 136 
systematically reviewed by the research team to ensure they met the eligibility criteria 137 
(supplementary material 2) and were subsequently used to inform this critical analysis and 138 
recommendations for future practice. Studies were only included if they reported a replicable 139 
NMES protocol. In addition, recently published guidelines recommending the use of home 140 
based NMES for chronic respiratory conditions such as chronic obstructive pulmonary disease 141 
(COPD) from the National Institute of Clinical Excellent (NICE) were used to inform 142 
recommendations (12). A narrative review was considered the most appropriate methodology 143 
so that the research team could use a broad survey of the literature, in combination with expert 144 
opinion, to inform clinical recommendations. The research team is a multinational, 145 
multidisciplinary group of experts with many years clinical experience of NMES. The group 146 
includes biomedical engineers; physiotherapists; intensive care clinicians; physiologists and 147 
haematologists.   148 
 149 
Recommendations 150 
Physiological considerations  151 
Fundamental to the treatment with NMES is an understanding of the electrophysiological 152 
mechanisms associated with skeletal muscle function. Skeletal muscles, including diaphragm 153 
and accessory respiratory muscles, are made up of long, multinucleate, approximately 154 
cylindrical cells containing sarcomeres in which the contractile proteins actin and myosin 155 
interact to generate force and shortening. Skeletal muscle powers voluntary movement, 156 
including speech and breathing, buffers circulating glucose, and is surprisingly labile. Disuse 157 
during bedrest causes loss of muscle mass by active cellular mechanisms. This presents a severe 158 
problem in ventilated patients. The domed diaphragm muscle normally flattens by shortening 159 
to generate a lower than atmospheric pressure in the pleural space, so the lungs inflate. During 160 
mechanical ventilation it quickly loses mass so that after ventilatory assistance, diaphragm 161 
function is reduced (13). The extreme reduction in activity from contraction during every 162 
breath, to zero, may explain why the diaphragm loses mass more quickly than, say, the pectoral 163 
muscles. In healthy persons, growth of muscle is often considered to be slower than the loss of 164 
muscle with disuse; to gain 1kg of leg muscle might take 12 weeks of resistance training, 165 
whereas 1kg of mass is lost in one week with complete disuse (14). The magnitude of the 166 
difference in activity before and after is very different in these scenarios, so prevention of 167 
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atrophy with early activity-based methods may reduce the human and financial cost of 168 
rehabilitation after critical illness. 169 
 170 
To activate muscle contractions from outside the body, action potentials must be generated in 171 
the muscle membrane. Stimulation is usually applied where the nerve that contains the target 172 
motor neurones is most accessible. Muscles respond to single action potentials with a brief 173 
period of activation then relaxation. The force response to a single stimulus is a very brief 174 
twitch with a low force. To produce stronger contractions, successive activations must be 175 
applied before the relaxation of the prior stimulus, and so frequencies in humans of 20-50 176 
impulses per second are used (20-50Hz). Muscles require a continuous supply of oxygen and 177 
glucose to generate sustained work, and therefore contractions must be intermittent, because 178 
blood flow is excluded during strong contractions. The activity/rest cycle and the number of 179 
contractions in a session provides a huge number of possible combinations. Exercise is often 180 
prescribed in terms of a number of sets of repetitions (single contractions), with a rest period 181 
between sets. As a result, unless otherwise stated, cyclic electrical stimulation was used in the articles 182 
considered in this review, rather than any other NMES (for example, EMG-triggered stimulation).  183 
 184 
Neuromuscular electrical stimulation and intensive care unit acquired weakness  185 
The application of NMES to treat ICUAW is well documented within the evidence-base (15-186 
18). The primary objective of interventions has been to induce intermittent muscle contractions 187 
with electrical stimulation to minimize the loss of muscle mass and excitability, to strengthen 188 
these muscles and to enhance the recovery of mobility during and after discharge from the ICU 189 
(19). The findings from pre-clinical work on underlying electrophysiological mechanisms from 190 
healthy participants and data from critical care patients suggest that to prevent ICUAW, an 191 
NMES program should begin in the ICU as soon as medically feasible. This is particularly 192 
relevant to people with C-19, as early intervention is advised due to the often-prolonged stay 193 
and risk for subsequent long-term ICUAW. Reducing initial muscle atrophy is preferable to 194 
extending rehabilitation due to the extended amount of time it takes to recover pre-ICU muscle 195 
strength (20). Those with risk factors for ICUAW should be prioritised because there is a small amount 196 
of evidence that NMES can reduce the prevalence of ICUAW (21). 197 
 198 
Many studies have activated the quadriceps (Figure 1) along with another muscle group such 199 
as the hamstrings, whereas others have targeted the abdominal musculature. Stimulation 200 
parameters commonly used are a frequency between 30-50Hz, pulse duration of 250-400 µs 201 
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and an intensity adjusted up to maximum sensory tolerance so that contractions are easily 202 
visible and palpable. Most studies have included one hour-long session or two 30 minutes 203 
sessions per day. There has been enough commonality to conduct systematic reviews and a 204 
meta-analysis using the Medical Research Council’s (MRC) score for muscle strength as an 205 
outcome measure. Liu et al. (15) found a significant improvement in muscle strength for NMES 206 
over control (mean difference (MD)=1.78, 95% CI 0.44, 3.12 (p = 0.009)). All studies included 207 
in the review used the MRC scale to evaluate the strength of the surrounding muscles, with a 208 
score of <48 to diagnose ICUAW (22-26). Several previously conducted systematic reviews in 209 
the area are largely consistent with these findings (16-18). 210 
 211 
The current most commonly protocols on the ICU, suggest that NMES at this stage for a limited 212 
amount of time might be sufficient to maintain muscle volume but not increase it. In one of the 213 
larger studies conducted, Dall’Acqua et al. (27) did not find a significant improvement in 214 
abdominal muscle thickness for NMES but interestingly found a significant decline in the 215 
control. Further support for this hypothesis is suggested in a recent study from Nakamura et al, 216 
(28) who examined the effects of a 20-minute daily dose of NMES (171 contractions per day) 217 
on femoral muscle volume. Researchers found a significant decrease in muscle volume for both 218 
the control and intervention group; however, the mean rate of muscle volume reduction was 219 
significantly less for the NMES group (NMES (standard deviation (SD)=10.4% (SD 10.1%), 220 
control=17.7% (SD 10.8%) (p=0.04)). The data from these studies and longer-term treatment, 221 
for example, up to nine weeks (29) suggests that NMES can be used in the ICU to slow down 222 
muscle wasting but it is necessary for participants to then use home based NMES to maintain 223 
and strengthen muscles post-ICU. Interestingly, recent research by Nakashini et al. (30) 224 
suggests that identifying the motor-point to elicit the strongest contraction, as well as increasing 225 
the number of contractions in a session, may maintain muscle strength more effectively. 226 
Researchers included a 30-minute daily session (180 contractions) for five days to the NMES 227 
group while the control had usual care. A significant difference in muscle volume and strength 228 
was found but no difference in ICUAW was found. This suggests that further research should 229 
be conducted into optimal dosing for ICU patients and is supportive of a period of post ICU 230 
NMES treatment for maintenance and recovery of strength.  231 
 232 
Neuromuscular electrical stimulation in chronic obstructive pulmonary disease  233 
As Covid-19 is a chronic respiratory condition, patients may share some similarities with 234 
COPD patients in terms of symptoms and complications (for example, shortness of breath, 235 
Page 8 of 27 
 
respiratory infection, heart problems and peripheral muscle weakness) and thus it is beneficial 236 
to review the evidence for NMES within COPD patient groups. Recently published NICE 237 
guidelines for the use of NMES to strengthen muscles in patients with chronic respiratory 238 
disease recommend that for those who are unable to exercise, evidence supports the use of 239 
electrical muscle stimulation. However,  standard arrangements must be in place for clinical 240 
governance, consent and audit (12). A meta-analysis of nine studies including 276 patients with 241 
moderate-to-severe COPD found improvement in quadriceps muscle strength (standardised 242 
mean difference (SMD)=1.12, 95% CI 0.64 to 1.59 (p<0.001); 6 studies of 207 patients) with 243 
NMES (31). In a recent Cochrane review, improvements were found for peripheral muscle 244 
endurance (SMD=1.36, 95% CI 0.59 to 2.12, (p<0.001); 2 studies of 35 patients) and these 245 
improvements translated into improved 6-minute walking distance (MD=39.26m, 95% CI 246 
16.31 to 62.22, (p<0.001); 2 studies of 72 patients) (32). An improvement in exercise endurance 247 
was also found (MD=3.62 minutes, 95% CI 2.33 to 4.91, (p<0.001); 3 studies of 55 patients) 248 
and days to first transfer out of bed was decreased for the NMES group (MD=-4.98 days, 95% 249 
CI -8.55 to -1.41, (p=0.006); 2 studies of 44 patients) (32). However, NMES was not associated 250 
with improvements to health-related quality of life (32), and thus the actual value of NMES for 251 
improved quality of life remains uncertain (31).   252 
 253 
NMES stimulation parameters for COPD vary considerably among studies, with stimulation 254 
frequency set to a median value of 50Hz (range 15-75 Hz), pulse duration 400µs (200-700), 255 
target duty cycle 33% (13-75), session length 30 minutes (18-240), session frequency 5 times 256 
(2-7) each week, and programme duration 6 weeks (4-11) (31). All studies set stimulation 257 
amplitude to elicit a visible muscle contraction within the participant's tolerance and most 258 
found that the amplitude could be increased over the course of the programme. However, the 259 
high variability in length of time, parameters and different type of outcome measures used in 260 
the studies made comparison difficult.  261 
 262 
Neuromuscular electrical stimulation to wean critically ill patients off ventilators 263 
Neuromuscular electrical stimulation may be considered to help wean critically ill patients off 264 
ventilators and is advantageous when the patient cannot participate in voluntary exercise. 265 
Preliminary work supporting the added value of an NMES program to wean patients from 266 
dependence on ventilators is supportive of further research in this area. McCaughey et al. (33) 267 
provided the most credible, albeit preliminary data, that earlier weaning is possible. They 268 
applied NMES over the posterior-lateral abdominal wall to activate the transversus abdominis 269 
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and internal and external oblique muscles during exhalation, automatically synchronized with 270 
the participant’s breathing pattern. Stimulation was applied for 30 minutes, twice per day, five 271 
days per week, until discharge from the ICU. The study compared an active group receiving 272 
stimulation that caused a strong visible muscle contraction (30Hz frequency and a pulse-width 273 
of 350 μsec) to a control group that received sensory level stimulation (10 Hz frequency and 274 
350 μsec pulse-width, but with an amplitude sufficient to be felt on the skin but not to cause 275 
muscle contraction). A survival analysis found ICU length of stay (median 11 versus not 276 
estimable days, (p=0.011)) and ventilation duration (median 6.5 versus 34 days, (p=0.039)) 277 
were shorter in the intervention compared to the control group. Dall'Acqua and colleagues (27) 278 
stimulated the pectoral and rectus abdominis muscles bilaterally for 30 min daily, using 300 279 
µsec phase duration, 50 Hz pulse rate to induce a 3 second contraction followed by 10 seconds 280 
of relaxation and compared it to a sensory threshold stimulation group. Time to weaning off 281 
the ventilator was not recorded but the length of ICU stay was shorter in the NMES group 282 
(mean: 10 ± 4 days) compared to the control group (mean: 16 ± 9) (p=0.045). Other 283 
investigators used NMES to activate the deltoid and quadriceps muscles bilaterally, applied 284 
concurrently with active exercises or without exercises or exercise only and found no difference 285 
between groups in terms of time to discharge from the ICU (34). None of these three groups of 286 
investigators reported any adverse response or interference with the recovery of and discharge 287 
from the ICU.  288 
 289 
Neuromuscular electrical stimulation and venous thromboembolism prevention   290 
Venous thromboembolism (VTE), encompassing pulmonary embolism (PE) and deep venous 291 
thrombosis (DVT), is a common and severe complication of critical illness (35, 36). Many 292 
critically ill patients have multiple risk factors that predate ICU admission; including, recent 293 
surgery or trauma, sepsis, malignancy, immobilisation, increased age and cardiac or respiratory 294 
failure (37). Once admitted, patients that need treatment on the ICU are exposed to additional 295 
VTE risk factors, including prolonged immobilisation, pharmacological paralysis, central 296 
venous catheterisation, haemodialysis and treatment with vasopressors (37-39). In four recent 297 
meta-analyses of hospitalised C-19 patients, incidence of thrombotic complications was 298 
reported between 22.7%-31%, and risk persisted even in those receiving anticoagulation (40-299 
43).  300 
 301 
Prophylaxis aims to combat the three predisposing factors to VTE; venous stasis, 302 
hypercoagulability and endothelial injury (44). Traditional prevention strategies include 303 
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pharmacological agents such as unfractionated heparin, low molecular weight heparin 304 
(LMWH) direct oral anticoagulants, and mechanical devices such as graduated compression 305 
stockings or intermittent pneumatic compression of the limbs (45). Interim guidance for C-19 306 
recommends treatment with LMWH administered at prophylaxis doses pending the emergence 307 
of additional data and guidance (46). Despite receiving anticoagulation for 308 
thromboprophylaxis, a high rate of VTE has been observed among C-19 patients admitted to 309 
the ICU (43). NMES has been approved by NICE as an alternative prophylaxis when other 310 
mechanical and pharmacological methods of prophylaxis are impractical or contraindicated 311 
(47, 48). The transcutaneous application of electrical impulses stimulates the common peroneal 312 
nerve to generate dorsiflexion in the lower limb, which in turn activates the calf muscle pump 313 
emulating the normal physiological response achieved by walking, without the patient having 314 
to mobilise. NMES has been shown to be effective in reducing fibrinogen, D-Dimer and tPA 315 
levels, and increasing venous, arterial and microcirculatory flow, thus preventing venous stasis 316 
and oedema (49-58). Moreover, clinical evidence has shown effectiveness of NMES for 317 
reducing the incidence of DVT in hospitalised patients (59-66).  318 
 319 
In line with recommendations from NICE, NMES should be considered as an alternative or 320 
adjunct prophylaxis in C-19 patients where other mechanical and pharmacological prophylaxis 321 
are impractical (47). It may be most effective when used prior to the formation of oedema, to 322 
prevent venous stasis and reduce VTE risk. Devices should be used in accordance with 323 
guidance (47) and the individual instructions for use of specific devices. If NMES is used for 324 
other treatment aims (such as muscle strengthening), it should be acknowledged that a 325 
circulatory effect will be delivered simultaneously, and so competing treatment aims may be 326 
balanced by preferentially aiming NMES settings for muscle strengthening parameters. 327 
Furthermore, NMES may provide the most benefit to patients who are immobilised or 328 
positioned where the leg is lower than the body.  329 
 330 
Neuromuscular electrical stimulation and the continuum of care model 331 
Neuromuscular electrical stimulation may be advantageous in C-19 as it can be used throughout 332 
the patient’s recovery to address a number of physiological and clinical deficits (Figure 3) in a 333 
continuum of care model. Example applications of NMES for patients admitted to the ICU with 334 
C-19 are illustrated in Figure 4.   335 
While minimising the amount of stimulation is pragmatic on the ICU unit, following discharge, 336 
similarly to any exercise programme, NMES can be progressively increased subject to patient 337 
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tolerance and measurable benefits. As the patients begin to mobilize out of bed, a structured 338 
mobility program has been recommended (67). Adding the NMES to a structured physical 339 
exercise program appears advisable compared to applying the NMES in isolation (68). From a 340 
practical perspective, as long as the patient is non-responsive to verbal commands the NMES 341 
can be combined with passive range of motion (PROM) exercises.  Once responsive, the patient 342 
should be encouraged to add volitional contraction and active range of motion (AROM) 343 
combined with the NMES. In studies with neurological patients, volitional contraction has been 344 
found to be more effective at inducing useful therapeutic improvements (69).  345 
 346 
Following discharge from hospital, ongoing use of NMES may also be considered to address 347 
persistent symptoms and functional limitations. NMES can be applied independently in the 348 
home environment and is considered an attractive adjunct to enhance the hypertrophic effect 349 
of traditional exercise (10). Likewise, following discharge it may be appropriate to consider 350 
the ongoing use of NMES to increase blood flow and prevent oedema or DVT. Nonetheless, 351 
one of the main shortcomings of current research on NMES in the ICU is the lack of long-term 352 
follow-up because most studies only use NMES for the duration of hospital stay (5-14 days). 353 
This may be reflective of the lack of long-term rehabilitation and follow-up for these patients 354 
once they leave the ICU and hospital. Further research including long term follow-up should 355 
be conducted as currently it is unknown whether patients who appear to benefit during their 356 
stay in ICU continue to benefit after a relatively short period of treatment. Further research 357 
should also examine the potential benefits of home based NMES post-ICU as part of a 358 
continuum of care. Using NMES for a period of nine weeks such as in previous investigations 359 
(29) or for a minimum of six weeks as in many of the COPD studies may lead to sustained 360 
longer-term benefits (31). 361 
 362 
Practical considerations 363 
Early rehabilitation has been generally accepted as a safe and effective intervention in Critical 364 
Care (70-74). However, there are several practical issues that make the implementation of these 365 
interventions challenging, especially in those with C-19. Such issues include deep sedation for 366 
facilitating mechanical ventilation; delirium; prone positioning; access to appropriate number 367 
or type of personnel; physiological stability and obesity. An observation study in France 368 
demonstrated that 65% of those with C-19 admitted to Critical Care experienced delirium and 369 
therefore a significant number of patients presumably would have been unable to 370 
safely/successfully participate in active physiotherapy regimes while affected (75). 371 
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Furthermore, even passive interventions such as in-bed cycle ergometry are restricted to those 372 
in the supine position, rendering them unsuitable for C-19 patients for whom prone positioning 373 
for more than 12 hours per day is a widely accepted strategy for improving oxygenation (76). 374 
In addition, in-bed cycling is purely passive and although it will help maintain range of 375 
movement it will not increase muscle bulk or strength. Another consideration is weight 376 
restrictions on rehabilitation equipment, which may preclude the 7.9% of morbidly obese 377 
patients (3) admitted to Critical Care with C-19 from receiving a number of interventions. 378 
Finally, accepting that C-19 has resulted in an increase in intensive care admissions and 379 
physiotherapy demand, more efficient rehabilitation interventions and use of staff is required. 380 
 381 
Safety considerations 382 
Common equipment in an ICU includes mechanical ventilators to assist breathing through an 383 
endotracheal tube or a tracheostomy tube; monitors of cardiac functions; equipment for the 384 
constant monitoring of bodily functions; a web of intravenous lines, feeding tubes, nasogastric 385 
tubes, suction pumps, drains, and catheters; syringe pumps; and a wide array of drugs to treat 386 
the primary condition(s) of hospitalization. Accordingly, the clinical team must verify the 387 
compatibility of the stimulation system to ensure there is no interference with the electronic 388 
systems such as ECG and EEG monitors, pacemakers, defibrillators, or other implanted 389 
stimulators. Iwatsu et al. (77) provided evidence assuring the safety of stimulation in the ICU. 390 
Furthermore, none of the other published clinical trials that used non-invasive electrical 391 
stimulation in the ICU reported interference with the ICU equipment (27, 28, 30, 33, 34, 78). 392 
Interference with pacemakers and implantable cardioverter defibrillators appears to depend on 393 
the proximity of the electrodes to the implanted device; lower limb stimulation in particular 394 
appears safe in this group, but clinicians must be aware of, and monitor for, such an interaction 395 
(79) especially if stimulation of respiratory muscles is indicated. In addition, the stimulation 396 
system must meet all hygiene, disinfection and sterilization standards required by the hospital. 397 
When applying the electrical stimulation, clinicians must not apply the electrode over open 398 
wounds and should avoid any contact of the electrodes with external fixation hardware. In 399 
contrast, applying NMES over internal hardware appears safe (80, 81). Electrical stimulation 400 
is known to increase muscle perfusion and oxygen consumption in a similar way to light 401 
intensity exercise. Given that changes are small and reversible, it is likely to be safe in those 402 
receiving cardiovascular support, and studies in this cohort have not reported any adverse 403 
effects (78). Finally, when applying electrical stimulation to those with reduced consciousness, 404 
special care must be taken over skin integrity as the patient will not be able to report pain. 405 




Innovations that save time and improve the outcome of rehabilitation will alleviate the burden 408 
of suffering and economic damage caused by C-19. Current evidence suggests that NMES can 409 
reduce the rate of muscle atrophy for patients admitted to the ICU. Whilst the evidence for 410 
increasing muscle mass is less clear, reduction of atrophy is a worthwhile goal in the pursuit of 411 
expedited recovery and return to independence. For the immobilised patient, NMES increases 412 
blood flow, reduces oedema and can be used as an alternative prophylaxis in cases where 413 
traditional methods are contraindicated. Evidence suggests NMES may play a role in the 414 
weaning of patients from ventilators and should be continued in the post-acute and longer-term 415 
phases of recovery. As such, NMES may be a suitable treatment modality to implement within 416 
rehabilitation pathways for C-19, with consideration of the practical and safety issues 417 
highlighted within this review. Future research endeavours should aim to evaluate the specific 418 
application of NMES to C-19 patients, the longer-term effect of NMES and the most effective 419 
parameters to influence underlying electrophysiological mechanisms. 420 
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Table I. Risk factors for deconditioning and ICU associated weakness in C-19 in comparison 
to viral pneumonia(3) 
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Viral Pneumonia, 2017-19 
(N=5,782) 
Duration of advanced 
respiratory support, median 
days (IQR) 
13 (7,23) 9 (4,17) 
Multi-organ failure, % 40.8 26.3 
Age, mean (SD) 58.8 (12.7) 58 (17.4) 
Very severe comorbidities, 
% 
13.6 24 
Dependency prior to 
hospital admission, % 
10.3 26.4 




















Figure 1. Electrode positioning for electrical stimulation of the quadriceps (mannequin)  
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Figure 2. Electrode position for electrical stimulation of the peroneal stimulation for increased 
blood flow to the lower limb (mannequin) 
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Figure 3. Characteristics of a patient admitted to intensive care unit with Covid-19 
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Figure 4. Example neuromuscular electrical stimulation application for patients admitted to 
intensive care unit with Covid-19 by indication 
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Supplementary material 1 – Search strategy 669 
 670 
((heart failure) OR (chronic kidney disease) OR (critically ill) OR (critical illness) OR (multiple 671 
organ failure) OR (intensive care unit) OR (critical care) OR (ICU) OR (CCU) OR (intensive 672 
therapy unit) OR (ITU) OR (acute respiratory failure) OR (acute respiratory distress) OR 673 
(ARDS) OR (multiorgan failure) OR (mechanical ventilat*) OR (mobili*) OR (sepsis) OR 674 
(septic) OR (deep vein thrombosis) OR (DVT) OR (COPD) OR (COAD) OR (chronic 675 
obstruct* pulmonary disease) OR (chronic obstruct* airway disease) OR (chronic obstruct* 676 
airflow disease) OR (chronic obstruct* pulmonary disorder) OR (chronic obstruct* airway 677 
disorder) OR (chronic obstruct* airflow disorder) AND ((muscle strength) OR (muscle 678 
dysfunction) or (muscle atrophy) or (muscle degeneration) or (muscle deteriorate*) OR 679 
(intensive care unit acquired weakness) OR (ICUAW)) AND ((electrical stimulation) OR 680 
(neuromusc* stimulation) OR (function* stimulation)) 681 
 682 
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Supplementary material 2 – Inclusion/exclusion criteria  
 
Inclusion Criteria Exclusion Criteria 
Patient Population 
• Patients being treated for ICU-
acquired weakness with NMES 
• Patients with Chronic Illness such as 
COPD, heart failure, and CKD that 
were being treated using NMES/FES 
to improve muscle mass and prevent 
muscle atrophy 
• Patients that were being treated 
using NMES/FES to improve blood 
flow and oedema. 
• Patients with ICU-acquired 
weakness after an elective surgery.  
• Patients with stroke, multiple 




• Functional Electrical Stimulation or 
Neuromuscular Electrical 
Stimulation 
• Transcutaneous electrical nerve 
stimulation 
Outcome 
• Stimulation  parameters and the 
protocol used for the therapy  
• Studies that did not clearly specify 
the protocol or the FES/NMES 
intervention 
Methodology 
• Randomised controlled trials, 
systematic reviews and meta-
analyses, and clinical studies that 
used NMES for the intended patient 
group. 




• Published in the last 10 years 
• Published in the English language 
• Studies with human participants 
• Access to full texts 
• Animal studies 
• Conference abstracts 
• Protocols and non-clinical studies 
